Trium Capital LLP Catalent, Inc. Transaction History
Trium Capital LLP
- $791 Million
- Q2 2024
A detailed history of Trium Capital LLP transactions in Catalent, Inc. stock. As of the latest transaction made, Trium Capital LLP holds 28,144 shares of CTLT stock, worth $1.7 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
28,144Holding current value
$1.7 Million% of portfolio
0.2%Shares
1 transactions
Others Institutions Holding CTLT
# of Institutions
489Shares Held
165MCall Options Held
364KPut Options Held
837K-
Vanguard Group Inc Valley Forge, PA20.4MShares$1.24 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY15.4MShares$930 Million0.02% of portfolio
-
Nomura Holdings Inc Tokyo, M011MShares$666 Million1.22% of portfolio
-
State Street Corp Boston, MA7.34MShares$444 Million0.02% of portfolio
-
Barclays PLC London, X04.97MShares$301 Million0.09% of portfolio
About Catalent, Inc.
- Ticker CTLT
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 179,896,000
- Market Cap $10.9B
- Description
- Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...